Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030, marking its largest strategic investment since entering the market in 1993, aimed at expanding its pharmaceutical production and R&D footprint [2][4] Group 1: Investment Details - The investment will cover the entire value chain from drug discovery, clinical development to manufacturing, enhancing AstraZeneca's capabilities in cell therapy and antibody-drug conjugates [4][5] - The investment will significantly deepen AstraZeneca's R&D presence in China, linking over 500 clinical hospitals with its global strategic R&D centers in Beijing and Shanghai [4][5] - AstraZeneca's collaboration with CSPC Pharmaceutical Group could reach up to 18.5 billion USD (approximately 128.5 billion RMB), with an initial payment of 1.2 billion USD (approximately 8.4 billion RMB) [3][5] Group 2: Market Dynamics - China's pharmaceutical market is undergoing structural changes, with a record 76 innovative drugs approved by the National Medical Products Administration in 2025, indicating a trend towards diversified innovative therapies [3][6] - Approximately one-third of global licensing transactions are related to Chinese biopharmaceutical companies, with over 30% of clinical trials in cutting-edge fields like cell therapy and ADCs occurring in China [3][6] Group 3: Strategic Partnerships - AstraZeneca has formed partnerships with leading biotech companies in China, aiming to leverage local innovations and enhance global supply chains [5][6] - The company has engaged in 17 licensing collaborations with 15 Chinese partners since 2023, with contract values exceeding 10 billion USD in 2025 alone [5][6] Group 4: Innovation and Development - The investment aligns with China's "Healthy China 2030" initiative, focusing on improving disease prevention, early screening, and accessibility of innovative drugs [10][12] - AstraZeneca's R&D pipeline in China has grown significantly, with over 200 projects, and is expected to yield around 20 new drug approvals by 2030 [7][9] Group 5: Industry Impact - AstraZeneca's investment reflects the ongoing opening of the Chinese pharmaceutical market, supported by favorable policies and reforms that enhance the R&D environment [7][10] - The company has invested in 31 Chinese innovative enterprises through its medical industry fund, facilitating 17 global licensing collaborations worth over 13.7 billion USD [9][10]

Core Viewpoint - The strategic collaboration between CSPC Pharmaceutical Group and AstraZeneca, valued at up to $18.5 billion, was met with unexpected market skepticism, leading to a significant drop in stock prices for both companies involved [2][4][7]. Group 1: Strategic Collaboration Details - CSPC Pharmaceutical Group announced a strategic partnership with AstraZeneca to co-develop innovative long-acting peptide drugs based on CSPC's drug delivery technology and AI discovery platform [3][4]. - The agreement includes a $1.2 billion upfront payment, up to $3.5 billion in research milestone payments, and $13.8 billion in sales milestone payments, along with a double-digit revenue share based on annual net sales [4][5]. - This deal surpasses the previous record of $11.4 billion set by Innovent Biologics and Takeda in 2025, marking a new high for outbound licensing in China's biopharmaceutical sector [4]. Group 2: Market Reaction and Concerns - Following the announcement, CSPC's stock fell by 9.82% to HKD 9.64 per share, while its closely related company, New Horizon Health, saw a drop of 15.72% [2][7]. - Analysts suggest that the market's negative reaction stems from concerns over the details of the deal and the companies' fundamentals, indicating that the perceived benefits may not align with the actual risks involved [7]. - The milestone payments are contingent on successful clinical trials and market performance, raising questions about the viability of CSPC's projects in a competitive landscape [7][8]. Group 3: Product and Competitive Landscape - The core asset in this collaboration is SYH2082, a long-acting weight management drug currently in Phase I clinical trials, targeting GLP-1R and GIPR receptors [8][9]. - The competitive landscape for GLP-1 drugs is intensifying, with major players like Eli Lilly and domestic companies rapidly advancing their own dual-target and multi-target drugs [9][10]. - CSPC's late entry into the clinical phase with SYH2082 presents challenges in efficacy differentiation and safety optimization, which will be critical for its future competitiveness [10]. Group 4: Financial Context and Implications - CSPC's decision to pursue this significant licensing deal comes at a time when its financial performance is under pressure, with a reported revenue decline of 12.32% year-on-year for the first three quarters of 2025 [11]. - New Horizon Health stands to benefit from the upfront payment, which will help alleviate its cash flow issues as it anticipates a significant net loss in 2025 due to high R&D expenditures [12].

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Increase" for 药明康德 (WuXi AppTec) [12][60]. Core Insights - The report highlights significant collaborations in the innovative drug sector, including 石药集团 (Shijiazhuang Yiling Pharmaceutical) partnering with AstraZeneca for long-acting peptide drug development and receiving clinical trial approval for SYS6055 injection in China [8][37]. - The report emphasizes the robust R&D capabilities of Chinese pharmaceutical companies showcased at the 2026 JPM Healthcare Conference, suggesting investment opportunities in innovative drugs, CXO, and upstream life sciences [12][60]. - The report notes the recent release of the revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China," which aims to enhance drug innovation and regulatory processes [19][20]. Industry Data - As of January 29, 2026, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) is 51.60 times, with a valuation premium of 259% relative to the CSI 300 index [10][52]. - The report provides current prices for vitamin raw materials, with Vitamin B1 at 237.5 RMB/kg and Vitamin D3 at 130 RMB/kg, remaining stable compared to January 28 [22]. - The Chinese herbal medicine market index shows a decline of 15% year-on-year, with specific herbs like 党参 (Codonopsis) and 当归 (Angelica) experiencing price drops of 41% and 29% respectively [26]. Company Announcements - 先声药业 (Xiansheng Pharmaceutical) signed an exclusive licensing agreement with Boehringer Ingelheim for the dual-specific antibody SIM0709, with potential milestone payments reaching up to 1.016 billion euros [36]. - 恒瑞医药 (Hengrui Medicine) received acceptance for a drug listing application and clinical trial approval for multiple products, including a breakthrough therapy designation for HRS-5346 [39][40]. - 诺诚健华 (Innovent Biologics) anticipates a revenue of approximately 2.365 billion RMB for 2025, marking a 134% year-on-year increase [41].

孟科含 Kehan Meng 聂照亿 Zhaoyi Nie kh.meng@htisec.com john.zy.nie@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_Title] 研究报告 Research Report 30 Jan 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 长效多肽产品组合授权阿斯利康，加速全球创新药布局 Long-Acting Peptide Product Portfolio Out-licensed to AZ, Accelerating Global Innovative Drug Deployment [Table_summary] (Please see APPENDIX 1 for English summary) 事件 石药创新（新诺威 300765.SZ，石药集团的控股子公司）的控股子公司巨石生物及石药集团、中奇制药（石药集团 的全资控股子公司）共同与阿斯利康签署《战略合作与授权协议》，将与阿斯利康在创新多肽分子发现和长效递 送产品的开发领域开展全面战略合作。 ...

1月30日，新诺威（300765）及其间接控股股东石药集团相继公告，宣布与全球生物制药巨头阿斯利康 (AstraZeneca)签署战略研发合作与授权协议，将在创新多肽分子发现和长效递送产品的开发领域开展全 面战略合作。 合作总金额 最高可达185亿美元 根据石药集团公告，在中国以外，阿斯利康将获得该集团"每月一次注射用体重管理产品组合"的全球独 家权利——包括一个临床准备就绪的项目SYH2082(长效GLP1R/GIPR激动剂，正推进至I期临床)，以及 三个处于临床前阶段、具备不同作用机制的研发项目。 根据石药集团公告，阿斯利康将向石药集团支付12亿美元预付款。此外，石药集团有权获得最高35亿美 元的潜在研发里程碑付款和最高138亿美元的潜在销售里程碑付款，以及基于相关授权产品年净销售额 的最高达双位数比例的销售提成。若所有里程碑均达成，该合作总金额最高可达185亿美元。 针对此次合作，添翼数字经济智库高级研究员吴婉莹对记者表示，此次石药集团与阿斯利康创纪录的战 略合作，标志着其"创新+国际化"战略取得里程碑式突破，不仅以巨额合作金额强力验证了其AI药物发 现与缓释给药等前沿技术平台的全球竞争力，为正处于传统 ...

Investment Rating - The report maintains a positive outlook on the overseas education sector, particularly highlighting key companies in the education and training industry [1]. Core Insights - The overseas education sector has shown significant improvement in operational efficiency, with a focus on key companies in the education and training industry [1]. - New Oriental (09901.HK) reported a revenue of $1.191 billion for Q2 FY26, a year-on-year increase of 14.7%, with a Non-GAAP net profit of $73 million, reflecting a 68.6% increase [6]. - Oriental Selection (01797.HK) achieved a revenue of 2.31 billion yuan in 1H FY26, up 5.7% year-on-year, and turned a profit with a net profit of 239 million yuan [9]. Summary by Sections 1. Overseas Education - The education index surged by 7.2% in the week of January 23-29, outperforming the Hang Seng Index by 2.2 percentage points [5]. - New Oriental's education business (including cultural tourism) generated $974 million, a 13% increase year-on-year, while other businesses (mainly Oriental Selection) saw a 22.9% revenue growth [6]. - The study abroad business's revenue growth has stabilized, with a 1% increase year-on-year, although it has slowed compared to previous periods [6]. 2. Oriental Selection - The company reported a revenue of 2.31 billion yuan in 1H FY26, marking a 5.7% increase year-on-year, and achieved profitability with a net profit of 239 million yuan [9]. - The gross merchandise volume (GMV) from self-operated products reached 2.16 billion yuan, with a significant improvement in gross margin from 21.5% to 33.7% year-on-year [10]. - The company is expanding its product offerings and enhancing operational efficiency, with a focus on increasing the utilization rate of existing teaching sites [7]. 3. Overseas Pharmaceuticals - The report highlights a strategic R&D collaboration between CSPC Pharmaceutical Group and AstraZeneca, valued at $18.5 billion, focusing on innovative long-acting peptide drugs [3][19]. - The agreement includes a $1.2 billion upfront payment and potential milestone payments totaling up to $13.8 billion, along with sales royalties based on net sales [19]. 4. Overseas Social Services - Macau's gaming revenue maintained double-digit growth, with December's gross gaming revenue reaching 20.9 billion MOP, a 14.8% year-on-year increase [23]. - The total visitor count for Macau in 2025 reached 40.06 million, a 14.7% increase year-on-year, marking a historical high [23].

[Table_Title] 研究报告 Research Report 30 Jan 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 长效多肽产品组合授权阿斯利康，加速全球创新药布局 Long-Acting Peptide Product Portfolio Out-licensed to AZ, Accelerating Global Innovative Drug Deployment 孟科含 Kehan Meng 聂照亿 Zhaoyi Nie 3）双方还将依托该等平台就另外四个新增项目开展合作。 kh.meng@htisec.com john.zy.nie@htisec.com 交易对价 [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件 石药创新（新诺威 300765.SZ，石药集团的控股子公司）的控股子公司巨石生物及石药集团、中奇制药（石药集团 的全资控股子公司）共同与阿斯利康签署《战略合作与授权协议》，将与阿斯利康 ...

Core Insights - AstraZeneca has announced a collaboration with China National Pharmaceutical Group (CSPC) for a licensing agreement valued at up to $18.5 billion, focusing on the development of obesity and diabetes medications [1][2] - The partnership will leverage CSPC's proprietary sustained-release drug delivery technology and AI drug discovery platform to jointly develop innovative long-acting peptide drugs [1] - This agreement marks CSPC's largest business development deal to date, with potential total payments reaching $18.5 billion if all milestones are achieved [2] Financial Aspects - CSPC will receive an upfront payment of $1.2 billion, with the potential for up to $3.5 billion in research milestone payments and up to $13.8 billion in sales milestone payments, along with a double-digit percentage royalty on annual net sales of the licensed products [1][2] - The deal is expected to significantly support AstraZeneca's pipeline for obesity drugs, which currently includes three candidates at various stages of development [5] Market Context - The global obesity drug market is projected to reach $100 billion by 2030, indicating a rapidly growing sector where AstraZeneca aims to compete against established players like Novo Nordisk and Eli Lilly [5] - The collaboration is part of a broader trend where multinational pharmaceutical companies are increasingly investing in the Chinese market, driven by the need for high-quality drug pipelines amid patent expirations and declining R&D efficiency [6][7] Strategic Importance - AstraZeneca plans to invest $15 billion in the Chinese market by 2030 to enhance its capabilities in drug production and R&D, which is crucial for achieving its goal of launching 20 innovative drugs by that year [6] - The partnership with CSPC is seen as a complement to AstraZeneca's investment strategy in China, reinforcing its commitment to local innovation and development [6] Industry Trends - By 2025, China's innovative drug licensing transactions are expected to exceed $130 billion, reflecting a significant increase in the number of deals and the value of Chinese biotech assets [7] - The shift from simple licensing to more complex collaborations indicates that Chinese pharmaceutical companies are poised to capture a larger share of the global pharmaceutical value chain [7][8]

Core Viewpoint - AstraZeneca has announced a collaboration with China National Pharmaceutical Group (CSPC) to develop obesity and diabetes drugs, with a maximum value of $18.5 billion, aiming to strengthen its position in a rapidly growing market [1][2]. Group 1: Collaboration Details - The agreement allows AstraZeneca exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) to develop, produce, and commercialize a weight management product portfolio, including one project entering clinical trials and three preclinical projects [1]. - CSPC will receive a $1.2 billion upfront payment, with potential milestone payments of up to $3.5 billion for development and $13.8 billion for sales, plus a double-digit percentage royalty based on annual net sales of the licensed products [1][2]. Group 2: Market Context - If all milestones are achieved, CSPC could receive a total of $18.5 billion, making it the largest business development deal for the company to date [2]. - The deal is expected to surpass recent significant transactions in the obesity drug market, including Pfizer's acquisition of a weight loss drug startup for over $10 billion [5]. Group 3: Strategic Importance - This collaboration supports AstraZeneca's pipeline for obesity drugs, with three treatments currently in various stages of development, and positions the company to compete in a market dominated by Novo Nordisk and Eli Lilly [5]. - Analysts predict that the global obesity drug market could reach $100 billion by 2030, highlighting the strategic importance of this collaboration for AstraZeneca [5]. Group 4: Investment in China - AstraZeneca plans to invest $15 billion in the Chinese market by 2030 to enhance its capabilities in drug production and research, which is crucial for achieving its goal of launching 20 innovative drugs by 2030 [6]. - The partnership with CSPC is seen as a complement to this investment strategy, reflecting the increasing focus of multinational pharmaceutical companies on the Chinese market [6]. Group 5: Industry Trends - The Chinese pharmaceutical market is experiencing a surge in innovation, with projections indicating that by 2025, the total value of innovative drug licensing transactions will exceed $130 billion [7]. - The industry is evolving from simple licensing agreements to more complex collaborations, allowing Chinese pharmaceutical companies to capture a larger share of the global pharmaceutical value chain [7][8].

Market Overview - The Hong Kong stock market experienced a high-level adjustment, with the Hang Seng Index falling by 2.08% to 27,387.11 points, the Hang Seng China Enterprises Index down by 2.47%, and the Hang Seng Tech Index decreasing by 2.1% [1][2]. Performance of Major Tech Stocks - Major tech stocks led the market decline, with Kuaishou and Xiaomi dropping over 3%, while Alibaba and Tencent fell by more than 2%. Other companies like Baidu, Meituan, and NetEase also followed suit [2][3]. Sector Performance - The market saw a broad decline across various sectors, particularly in precious metals and non-ferrous metals, which experienced significant pullbacks. Key sectors such as AI applications and finance also weakened, alongside consumer electronics, automotive, and pharmaceuticals [4][5][6]. Short Selling Activity - The total short selling amount reached 29.507 billion HKD, accounting for 9.78% of the Hang Seng Index's trading volume. The top three companies with the highest short selling amounts were CSPC Pharmaceutical, Zijin Mining, and Xiaomi Group, with short selling amounts of 1.268 billion HKD, 1.031 billion HKD, and 1.014 billion HKD respectively [4]. Precious Metals Market - The precious metals sector faced severe adjustments, with gold and silver prices experiencing significant declines. Spot gold dropped by 7.95% to 4,949.62 USD per ounce, while spot silver fell by 16.93% to 95.86 USD per ounce, reaching a low of 95 USD [8]. Future Market Outlook - The market sentiment remains cautious due to fluctuating expectations regarding the Federal Reserve's interest rate decisions and regulatory policies in mainland China. The volatility in the Hong Kong market is expected to persist in the short term, with a focus on stocks that possess core competitiveness and long-term value [9].